Bioluminescent orthotopic model of pancreatic cancer progression.

TitleBioluminescent orthotopic model of pancreatic cancer progression.
Publication TypeJournal Article
Year of Publication2013
AuthorsChai MG, Kim-Fuchs C, Angst E, Sloan EK
JournalJ Vis Exp
Date Published2013
KeywordsAnimals, Collagen, Disease Progression, Drug Combinations, Female, Firefly Luciferin, Laminin, Luciferases, Luminescent Agents, Luminescent Measurements, Male, Mice, Neoplasm Transplantation, Pancreatic Neoplasms, Proteoglycans, Transduction, Genetic

Pancreatic cancer has an extremely poor five-year survival rate of 4-6%. New therapeutic options are critically needed and depend on improved understanding of pancreatic cancer biology. To better understand the interaction of cancer cells with the pancreatic microenvironment, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression. Luciferase-tagged pancreatic cancer cells are resuspended in Matrigel and delivered into the pancreatic tail during laparotomy. Matrigel solidifies at body temperature to prevent leakage of cancer cells during injection. Primary tumor growth and metastasis to distant organs are monitored following injection of the luciferase substrate luciferin, using in vivo imaging of bioluminescence emission from the cancer cells. In vivo imaging also may be used to track primary tumor recurrence after resection. This orthotopic model is suited to both syngeneic and xenograft models and may be used in pre-clinical trials to investigate the impact of novel anti-cancer therapeutics on the growth of the primary pancreatic tumor and metastasis.

Alternate JournalJ Vis Exp
PubMed ID23852391
PubMed Central IDPMC3734868
Grant ListCA138687-01 / CA / NCI NIH HHS / United States
R01 CA160890 / CA / NCI NIH HHS / United States